Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3091 participants.
Also called NCT01541956
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,091 participants
- Sponsor
- Registry
-
NCT01541956
-
- Other papers using this trial's data
- Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01541956. Randomized; no masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- vildagliptin
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01541956- Content hash
134e140dad379c075fa00c01f5575df54d52c66bfe2174b5737065c77b73c52a